Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...
For the first time, real-world data on the Medtronic Extended Infusion™ Set was presented (n=108) and the analysis showed an average infusion set wear time of 6.74 days. Almost half (48.2%) of the ...
A real-world retrospective analysis published in Diabetes Care found that Medtronic’s MiniMed 780G insulin system users met American Diabetes Association time-in-range goals even on days when mealtime ...
GALWAY, Ireland, Dec. 2, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated ...
Medtronic has secured a green light from the FDA to connect its latest automated insulin pump with its newest continuous glucose monitor, following a similar approval for the pairing in Europe early ...
Medtronic plc MDT recently announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic ...
Medtronic (MDT) announced two FDA regulatory milestones that broaden the MiniMed 780G system portfolio: clearance of the SmartGuard algorithm as an interoperable automated glycemic controller, ...
Medtronic has commercially launched its MiniMed 780G system in the US, now integrated with Abbott’s Instinct sensor. The Instinct sensor utilises Abbott’s continuous glucose monitoring (CGM) ...
A first-of-its-kind meta-analysis comparing multiple automated insulin delivery (AID) systems in people with type 1 diabetes has found that Medtronic's MiniMed 780G achieved the highest time in target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results